Greenyn Competitors

Stocks . Taiwan . 
Stock . Greenyn Biotechnology Co
6846 Stock   73.90  0.30  0.40%   
Greenyn Biotechnology competes with Chunghwa Chemical, Genomics BioSci, Winston Medical, Crystalvue Medical, and Tsh Biopharmoration; as well as few others. Analyzing Greenyn Biotechnology competition allows you to expand the diversification possibilities of your existing portfolios and to get a better perspective on locking in new positions. Investors sometimes prefer comparable analysis of Greenyn Biotechnology to its intrinsic valuation because they are able to contrast its competitors on a relative basis. Check out Trending Equities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as various price indices.

Greenyn Biotechnology vs Chi Sheng Correlation

Good diversification

The correlation between Greenyn Biotechnology Co and 4111 is -0.02 (i.e., Good diversification) for selected investment horizon. Overlapping area represents the amount of risk that can be diversified away by holding Greenyn Biotechnology Co and 4111 in the same portfolio, assuming nothing else is changed.

Moving together with Greenyn Stock

  0.616505 Formosa PetrochemicalPairCorr

Greenyn Biotechnology Competition Correlation Matrix

Typically, diversification allows investors to combine positions across different asset classes to reduce overall portfolio risk. Correlation between Greenyn Biotechnology and its competitors represents the degree of relationship between the price movements of corresponding stocks. A correlation of about +1.0 implies that the price of Greenyn and its corresponding peer move in tandem. A correlation of -1.0 means that prices move in opposite directions. A correlation of close to zero suggests that the price movements of assets are uncorrelated; in other words, the historical price movement of Greenyn Biotechnology does not affect the price movement of the other competitor.

High positive correlations

6527
+ 0.77
6709
4111
+ 0.72
6527
4111
+ 0.7
6709
6527
+ 0.61
6676
4724
+ 0.59
8432
4111
+ 0.57
1762
  

High negative correlations

6934
- 0.79
6817
6934
- 0.77
8432
8432
- 0.7
6676
8432
- 0.68
6527
4724
- 0.59
6934
8432
- 0.44
6709

Risk-Adjusted Indicators

There is a big difference between Greenyn Stock performing well and Greenyn Biotechnology Company doing well as a business compared to the competition. There are so many exceptions to the norm that investors cannot definitively determine what's good or bad unless they analyze Greenyn Biotechnology's multiple risk-adjusted performance indicators across the competitive landscape. These indicators are quantitative in nature and help investors forecast volatility and risk-adjusted expected returns across various positions.
Mean DeviationJensen AlphaSortino RatioTreynor RatioSemi DeviationExpected ShortfallPotential UpsideValue @RiskMaximum Drawdown
6709  1.71 (0.39) 0.00 (0.58) 0.00 
 0.00 
 3.20 
(3.71)
 16.90 
1762  0.60 (0.03) 0.00 (0.32) 0.00 
 0.00 
 1.41 
(1.16)
 3.41 
4195  1.40 (0.19) 0.00 (3.56) 0.00 
 0.00 
 3.80 
(3.21)
 8.92 
6676  2.20  0.39  0.11 (5.33) 2.06 
(2.94)
 5.26 
(4.47)
 19.87 
6817  1.31 (0.52) 0.00 (1.77) 0.00 
 0.00 
 3.25 
(3.49)
 8.49 
6527  0.64 (0.14) 0.00 (1.33) 0.00 
 0.00 
 2.01 
(1.10)
 5.09 
8432  0.88  0.04 (0.06)(0.17) 1.08 
(1.09)
 1.85 
(1.45)
 8.37 
6934  4.77  2.48  0.43 (3.02) 2.99 
(5.55)
 18.06 
(8.04)
 45.51 
4724  1.38 (0.05) 0.00 (0.25) 0.00 
 0.00 
 5.26 
(3.72)
 14.75 
4111  0.47 (0.04) 0.00 (3.86) 0.00 
 0.00 
 0.68 
(1.03)
 2.17 

Greenyn Biotechnology Competitive Analysis

The better you understand Greenyn Biotechnology competitors, the better chance you have of utilizing it as a position in your portfolios. From an individual investor's perspective, Greenyn Biotechnology's competitive analysis can cover a whole range of metrics. Some of these will be more critical depending on who you are as an investor and how you react to market volatility. However, if you are locking your investment sandscape to a long-term horizon, comparing the fundamental indicator across Greenyn Biotechnology's competition over several years is one of the best ways to analyze its investment potential.
    
 Better Than Average     
    
 Worse Than Peers    View Performance Chart
6846 6709 1762 4195 6676 6817 6527 8432 6934 4724
 0.40 
 73.90 
Greenyn
 7.18 
 28.35 
Advagene
 1.15 
 25.90 
Chunghwa
 0.81 
 24.45 
Genomics
 4.88 
 15.60 
Sunny
 2.39 
 81.50 
Winston
 0.66 
 76.80 
Crystalvue
 0.54 
 55.70 
Tsh
 3.33 
 155.00 
6934
 0.65 
 15.50 
Meribank
Market Volatility
(90 Days Market Risk)
Very steady
Very steady
Very steady
Out of control
Somewhat reliable
Very steady
Very steady
Very steady
Very steady
Not too volatile
Market Performance
(90 Days Performance)
Weak
Weakest
Weakest
Weakest
Fair
Weakest
Weakest
Weak
Solid
Weakest
Odds of Financial Distress
(Probability Of Bankruptcy)
Unknown
Fair
Low
Low
Unknown
Low
Low
Low
Unknown
Unknown
Current Valuation
(Equity Enterprise Value)
Fairly Valued
Fairly Valued
Fairly Valued
Under Valued
Over Valued
Fairly Valued
Fairly Valued
Over Valued
Over Valued
Over Valued
Buy or Sell Advice
(Average Analysts Consensus)
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Not Available
Trade Advice
(90 Days Macroaxis Advice)
Cautious Hold
Hold
Cautious Hold
Not Rated
Strong Sell
Cautious Hold
Cautious Hold
Strong Sell
Strong Sell
Strong Sell
Current Ratio
N/A
N/A
1.36
3.01
N/A
1.65
3.44
5.36
N/A
N/A
Net Asset
N/A
N/A
4.38 B
N/A
N/A
N/A
N/A
1.17 B
N/A
N/A
Profit Margin
N/A
N/A
0.23
N/A
N/A
24.57
11.53
0.15
N/A
N/A
EBITDA
N/A
N/A
632.93 M
25.55 M
N/A
177.79 M
89.04 M
71.41 M
N/A
N/A
Operating Margin
N/A
N/A
0.22
N/A
N/A
24.46
12.73
0.16
N/A
N/A
Current Valuation
N/A
N/A
5.19 B
N/A
N/A
1.22 B
1.16 B
1.17 B
N/A
N/A
Price To Book
N/A
N/A
1.56
N/A
N/A
4.51
3.26
1.77
N/A
N/A
Retained Earnings
N/A
N/A
630 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Current Asset
N/A
N/A
729 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Five Year Return
N/A
N/A
2.83
N/A
N/A
N/A
N/A
3.54
N/A
N/A
Beta
N/A
N/A
0.86
0.64
N/A
N/A
0.07
-0.0266
N/A
N/A
Number Of Employees
N/A
10
21
16
N/A
N/A
94
80
N/A
N/A
Shares Outstanding
N/A
N/A
77.56 M
N/A
N/A
18.17 M
21.05 M
38.4 M
N/A
N/A
Cash Flow From Operations
N/A
N/A
219.18 M
40.87 M
N/A
169.12 M
101.33 M
68.71 M
N/A
N/A
Annual Yield
N/A
N/A
0.0198
N/A
N/A
N/A
N/A
0.0319
N/A
N/A
Total Debt
N/A
N/A
600 M
86.52 M
N/A
136.16 M
N/A
7.01 M
N/A
N/A
Return On Equity
N/A
N/A
0.17
N/A
N/A
53.39
15.83
0.0635
N/A
N/A
Z Score
N/A
N/A
4.8
9.0
N/A
5.4
N/A
N/A
N/A
N/A
Return On Asset
N/A
N/A
0.066
N/A
N/A
13.76
8.26
0.0387
N/A
N/A
Book Value Per Share
N/A
N/A
39.98
12.89
N/A
16.2
21.6
27.67
N/A
N/A
Current Liabilities
N/A
N/A
617 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Total Asset
N/A
N/A
4.38 B
N/A
N/A
N/A
N/A
1.17 B
N/A
N/A
Debt To Equity
N/A
N/A
41.0
0.11
N/A
0.39
N/A
0.6
N/A
N/A
Target Price
N/A
N/A
125.0
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Last Dividend Paid
N/A
N/A
1.3
1.17
N/A
3.0
1.73
1.5
N/A
N/A
Shares Owned By Institutions
N/A
N/A
4.61
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Market Capitalization
N/A
879.46 M
5.17 B
1.34 B
N/A
1.33 B
1.48 B
1.78 B
N/A
N/A
Price To Earning
N/A
N/A
9.2
26.25
N/A
13.01
21.83
56.63
N/A
N/A
Price To Sales
N/A
N/A
2.37
N/A
N/A
2.26
2.45
4.22
N/A
N/A
Net Income
N/A
N/A
400.78 M
45.34 M
N/A
144.27 M
69.89 M
47.11 M
N/A
N/A
Earnings Per Share
N/A
N/A
6.21
0.72
N/A
5.62
3.23
1.78
N/A
N/A
Shares Owned By Insiders
N/A
N/A
39.75
N/A
N/A
N/A
N/A
64.94
N/A
N/A
Revenue
N/A
N/A
1.93 B
N/A
N/A
587.22 M
606.31 M
413.48 M
N/A
N/A
Working Capital
N/A
N/A
112 M
N/A
N/A
N/A
N/A
N/A
N/A
N/A
Cash And Equivalents
N/A
N/A
97.43 M
110.98 M
N/A
238.7 M
347.53 M
708.28 M
N/A
N/A
Cash Per Share
N/A
N/A
1.26
1.76
N/A
13.14
16.25
18.36
N/A
N/A
Gross Profit
N/A
N/A
949.39 M
N/A
N/A
203.82 M
187.94 M
247.36 M
N/A
N/A
Day Typical Price
74.17
27.98
26.02
24.55
15.8
81.1
76.53
55.53
154.17
15.27
Accumulation Distribution
317.58
18368.45
1605.08
3260.6
26957.53
1511.36
168.7
579.8
123160.0
3114.73
Market Facilitation Index
1.0E-4
0.0
0.0
0.0
0.0
2.0E-4
0.0
0.0
0.0
0.0
Daily Balance Of Power
(0.21)
0.6552
(0.67)
(0.33)
(0.67)
0.3654
0.625
0.3333
0.2857
0.1429
Period Momentum Indicator
(0.30)
1.9
(0.30)
(0.20)
(0.80)
1.9
0.5
0.3
5.0
0.1
Rate Of Daily Change
1.0
1.07
0.99
0.99
0.95
1.02
1.01
1.01
1.03
1.01
Day Median Price
74.3
27.8
26.08
24.6
15.9
80.9
76.4
55.45
153.75
15.15
Price Action Indicator
(0.55)
1.5
(0.33)
(0.25)
(0.70)
1.55
0.65
0.4
3.75
0.4
Relative Strength Index
49.8
46.41
58.27
44.56
N/A
N/A
44.24
47.97
N/A
N/A
Coefficient Of Variation
5701.8
(825.02)
(5,888)
(1,139)
936.37
(367.04)
(828.45)
3407.15
316.27
(9,874)
Mean Deviation
0.7434
1.71
0.5997
1.4
2.2
1.31
0.64
0.884
4.77
1.38
Jensen Alpha
(0.03)
(0.39)
(0.03)
(0.19)
0.3909
(0.52)
(0.14)
0.0421
2.48
(0.05)
Total Risk Alpha
(0.13)
(0.67)
(0.14)
(0.43)
(0.09)
(0.72)
(0.26)
(0.13)
1.43
(0.34)
Sortino Ratio
(0.08)
N/A
N/A
N/A
0.11
N/A
N/A
(0.06)
0.4307
N/A
Downside Variance
1.1
N/A
N/A
N/A
6.95
N/A
N/A
1.46
28.84
N/A
Standard Deviation
1.07
2.65
0.8739
1.97
3.69
1.79
1.01
1.26
7.64
2.41
Kurtosis
1.61
8.23
3.95
1.41
12.52
0.6159
4.05
3.56
8.97
7.64
Potential Upside
1.91
3.2
1.41
3.8
5.26
3.25
2.01
1.85
18.06
5.26
Treynor Ratio
0.0238
(0.58)
(0.32)
(3.56)
(5.33)
(1.77)
(1.33)
(0.17)
(3.02)
(0.25)
Maximum Drawdown
5.9
16.9
3.41
8.92
19.87
8.49
5.09
8.37
45.51
14.75
Variance
1.15
7.04
0.7637
3.9
13.62
3.19
1.02
1.59
58.43
5.79
Market Risk Adjusted Performance
0.0338
(0.57)
(0.31)
(3.55)
(5.32)
(1.76)
(1.32)
(0.16)
(3.01)
(0.24)
Risk Adjusted Performance
0.0161
(0.08)
(0.01)
(0.06)
0.0869
(0.20)
(0.09)
0.0258
0.2425
(0.0005)
Skewness
0.0069
1.88
1.31
0.3242
2.81
(0.06)
1.15
0.4145
2.35
1.93
Semi Deviation
0.9196
N/A
N/A
N/A
2.06
N/A
N/A
1.08
2.99
N/A
Information Ratio
(0.08)
(0.16)
(0.14)
(0.14)
0.0786
(0.33)
(0.22)
(0.05)
0.3026
(0.05)
Value At Risk
(1.71)
(3.71)
(1.16)
(3.21)
(4.47)
(3.49)
(1.10)
(1.45)
(8.04)
(3.72)
Expected Short fall
(1.02)
N/A
N/A
N/A
(2.94)
N/A
N/A
(1.09)
(5.55)
N/A
Downside Deviation
1.05
N/A
N/A
N/A
2.64
N/A
N/A
1.21
5.37
N/A
Semi Variance
0.8456
N/A
N/A
N/A
4.23
N/A
N/A
1.17
8.91
N/A

Greenyn Biotechnology Competition Performance Charts

Five steps to successful analysis of Greenyn Biotechnology Competition

Greenyn Biotechnology's competitive analysis is the process of researching and evaluating its competitive landscape. It provides an understanding of the strengths, weaknesses, opportunities, and threats (SWOT) faced by Greenyn Biotechnology in relation to its competition. Greenyn Biotechnology's competition analysis typically involves several steps, including:
  • Identifying the key players in the market: This involves identifying the major competitors of Greenyn Biotechnology in the market, both direct and indirect, as well as new entrants and disruptive technologies.
  • Assessing the strengths and weaknesses of each competitor: This involves evaluating each competitor's strengths and weaknesses in areas such as product offerings, market share, brand recognition, financial performance, and distribution channels.
  • Understanding the competitive environment: This involves evaluating the regulatory environment, economic conditions, and other factors that may impact Greenyn Biotechnology's competitive landscape.
  • Identifying opportunities and threats: This involves using the information gathered during the analysis to identify opportunities and threats to Greenyn Biotechnology, and developing a strategy to address them.
  • Evaluating the competitive landscape: This involves understanding the competitive dynamics of the market, such as pricing, marketing, and distribution strategies, as well as analyzing the competitive advantage of each competitor.
Competitive analysis is an essential tool for businesses to stay ahead of the competition and can be used to inform decision-making and strategy development. By understanding the competitive landscape and staying informed about the activities of competitors, a company can make more informed decisions and improve its overall performance.

Complement your Greenyn Biotechnology position

In addition to having Greenyn Biotechnology in your portfolios, you can quickly add positions using our predefined set of ideas and optimize them against your very unique investing style. A single investing idea is a collection of funds, stocks, ETFs, or cryptocurrencies that are programmatically selected from a pull of investment themes. After you determine your investment opportunity, you can then find an optimal portfolio that will maximize potential returns on the chosen idea or minimize its exposure to market volatility.

Did You Try This Idea?

Run High Dividend Yield ETFs Thematic Idea Now

High Dividend Yield ETFs
High Dividend Yield ETFs Theme
ETF themes focus on helping investors to gain exposure to a broad range of assets, diversify, and lower overall costs. The High Dividend Yield ETFs theme has 111 constituents at this time.
You can either use a buy-and-hold strategy to lock in the entire theme or actively trade it to take advantage of the short-term price volatility of individual constituents. Macroaxis can help you discover thousands of investment opportunities in different asset classes. In addition, you can partner with us for reliable portfolio optimization as you plan to utilize High Dividend Yield ETFs Theme or any other thematic opportunities.
View All  Next Launch

Additional Tools for Greenyn Stock Analysis

When running Greenyn Biotechnology's price analysis, check to measure Greenyn Biotechnology's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Greenyn Biotechnology is operating at the current time. Most of Greenyn Biotechnology's value examination focuses on studying past and present price action to predict the probability of Greenyn Biotechnology's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Greenyn Biotechnology's price. Additionally, you may evaluate how the addition of Greenyn Biotechnology to your portfolios can decrease your overall portfolio volatility.
Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions
 
Feedback Blog
Made with optimal in San Francisco
2026 Macroaxis LLC
COMMON DESTINATIONS
MAIN CATEGORIES
COMPANY